File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Use of aspirin in Chinese after recovery from primary intracranial haemorrhage
  • Basic View
  • Metadata View
  • XML View
TitleUse of aspirin in Chinese after recovery from primary intracranial haemorrhage
 
AuthorsChong, BH1
Chan, KH1
Pong, V1
Lau, KK1
Chan, YH1
Zuo, ML1
Lui, WM1
Leung, GKK1
Lau, CP1
Tse, HF1
Pu, JKS1
Siu, CW1
 
KeywordsAntiplatelet agents
Risk factors
Stroke/prevention
 
Issue Date2012
 
PublisherSchattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.com
 
CitationThrombosis And Haemostasis, 2012, v. 107 n. 2, p. 241-247 [How to Cite?]
DOI: http://dx.doi.org/10.1160/TH11-06-0439
 
AbstractIntracranial haemorrhage (ICH) accounts for ∼35% of all strokes in Chinese. Anti-platelet agent is often avoided after an index event due to the possibility of recurrent ICH. This single-centered observational study included 440 consecutive Chinese patients with a first spontaneous ICH surviving the first month performed during 1996-2010. The subjects were identified, and their clinical characteristics, anti-platelet therapy after ICH, and outcomes including recurrent ICH, ischaemic stroke, and acute coronary syndrome were checked from hospital records. Of these 440 patients, 56 patients (12.7%) were prescribed aspirin (312 patientaspirin years). After a follow-up of 62.2 ± 1.8 months, 47 patients had recurrent ICH (10.7%, 20.6 per 1,000 patient years). Patients prescribed aspirin did not have a higher risk of recurrent ICH compared with those not prescribed aspirin (22.7 per 1,000 patient-aspirin years vs. 22.4 per 1,000 patient years, p=0.70). Multivariate analysis identified age > 60 years (hazard ratio [HR]: 2.0, 95% confidence interval [CI]: 1.07-3.85, p=0.03) and hypertension (HR: 2.0, 95% CI: 1.06-3.75, p=0.03) as independent predictors for recurrent ICH. In a subgroup analysis including 127 patients with standard indications for aspirin of whom 56 were prescribed aspirin, the incidence of combined vascular events including recurrent ICH, ischaemic stroke, and acute coronary syndrome was statistically lower in patients prescribed aspirin than those not prescribed aspirin (52.4 per 1,000 patient-aspirin years, vs. 112.8 per 1,000 patient- years, p=0.04). In conclusion, we observed in a cohort of Chinese post-ICH patients that aspirin use was not associated with an increased risk for a recurrent ICH. © Schattauer 2012.
 
ISSN0340-6245
2012 Impact Factor: 6.094
2012 SCImago Journal Rankings: 2.077
 
DOIhttp://dx.doi.org/10.1160/TH11-06-0439
 
ISI Accession Number IDWOS:000300748800005
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorChong, BH
 
dc.contributor.authorChan, KH
 
dc.contributor.authorPong, V
 
dc.contributor.authorLau, KK
 
dc.contributor.authorChan, YH
 
dc.contributor.authorZuo, ML
 
dc.contributor.authorLui, WM
 
dc.contributor.authorLeung, GKK
 
dc.contributor.authorLau, CP
 
dc.contributor.authorTse, HF
 
dc.contributor.authorPu, JKS
 
dc.contributor.authorSiu, CW
 
dc.date.accessioned2012-02-03T06:13:42Z
 
dc.date.available2012-02-03T06:13:42Z
 
dc.date.issued2012
 
dc.description.abstractIntracranial haemorrhage (ICH) accounts for ∼35% of all strokes in Chinese. Anti-platelet agent is often avoided after an index event due to the possibility of recurrent ICH. This single-centered observational study included 440 consecutive Chinese patients with a first spontaneous ICH surviving the first month performed during 1996-2010. The subjects were identified, and their clinical characteristics, anti-platelet therapy after ICH, and outcomes including recurrent ICH, ischaemic stroke, and acute coronary syndrome were checked from hospital records. Of these 440 patients, 56 patients (12.7%) were prescribed aspirin (312 patientaspirin years). After a follow-up of 62.2 ± 1.8 months, 47 patients had recurrent ICH (10.7%, 20.6 per 1,000 patient years). Patients prescribed aspirin did not have a higher risk of recurrent ICH compared with those not prescribed aspirin (22.7 per 1,000 patient-aspirin years vs. 22.4 per 1,000 patient years, p=0.70). Multivariate analysis identified age > 60 years (hazard ratio [HR]: 2.0, 95% confidence interval [CI]: 1.07-3.85, p=0.03) and hypertension (HR: 2.0, 95% CI: 1.06-3.75, p=0.03) as independent predictors for recurrent ICH. In a subgroup analysis including 127 patients with standard indications for aspirin of whom 56 were prescribed aspirin, the incidence of combined vascular events including recurrent ICH, ischaemic stroke, and acute coronary syndrome was statistically lower in patients prescribed aspirin than those not prescribed aspirin (52.4 per 1,000 patient-aspirin years, vs. 112.8 per 1,000 patient- years, p=0.04). In conclusion, we observed in a cohort of Chinese post-ICH patients that aspirin use was not associated with an increased risk for a recurrent ICH. © Schattauer 2012.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationThrombosis And Haemostasis, 2012, v. 107 n. 2, p. 241-247 [How to Cite?]
DOI: http://dx.doi.org/10.1160/TH11-06-0439
 
dc.identifier.doihttp://dx.doi.org/10.1160/TH11-06-0439
 
dc.identifier.epage247
 
dc.identifier.hkuros198412
 
dc.identifier.isiWOS:000300748800005
 
dc.identifier.issn0340-6245
2012 Impact Factor: 6.094
2012 SCImago Journal Rankings: 2.077
 
dc.identifier.issue2
 
dc.identifier.pmid22187066
 
dc.identifier.scopuseid_2-s2.0-84856638385
 
dc.identifier.spage241
 
dc.identifier.urihttp://hdl.handle.net/10722/144558
 
dc.identifier.volume107
 
dc.languageeng
 
dc.publisherSchattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.com
 
dc.publisher.placeGermany
 
dc.relation.ispartofThrombosis and Haemostasis
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshAge Factors
 
dc.subject.meshAspirin - administration & dosage - adverse effects
 
dc.subject.meshFemale
 
dc.subject.meshFollow-Up Studies
 
dc.subject.meshHumans
 
dc.subject.meshIntracranial Hemorrhages - drug therapy - physiopathology - surgery
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPlatelet Aggregation Inhibitors - administration & dosage - adverse effects
 
dc.subject.meshRecurrence
 
dc.subject.meshRegistries
 
dc.subject.meshRisk Factors
 
dc.subject.meshTreatment Outcome
 
dc.subjectAntiplatelet agents
 
dc.subjectRisk factors
 
dc.subjectStroke/prevention
 
dc.titleUse of aspirin in Chinese after recovery from primary intracranial haemorrhage
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chong, BH</contributor.author>
<contributor.author>Chan, KH</contributor.author>
<contributor.author>Pong, V</contributor.author>
<contributor.author>Lau, KK</contributor.author>
<contributor.author>Chan, YH</contributor.author>
<contributor.author>Zuo, ML</contributor.author>
<contributor.author>Lui, WM</contributor.author>
<contributor.author>Leung, GKK</contributor.author>
<contributor.author>Lau, CP</contributor.author>
<contributor.author>Tse, HF</contributor.author>
<contributor.author>Pu, JKS</contributor.author>
<contributor.author>Siu, CW</contributor.author>
<date.accessioned>2012-02-03T06:13:42Z</date.accessioned>
<date.available>2012-02-03T06:13:42Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Thrombosis And Haemostasis, 2012, v. 107 n. 2, p. 241-247</identifier.citation>
<identifier.issn>0340-6245</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/144558</identifier.uri>
<description.abstract>Intracranial haemorrhage (ICH) accounts for &#8764;35% of all strokes in Chinese. Anti-platelet agent is often avoided after an index event due to the possibility of recurrent ICH. This single-centered observational study included 440 consecutive Chinese patients with a first spontaneous ICH surviving the first month performed during 1996-2010. The subjects were identified, and their clinical characteristics, anti-platelet therapy after ICH, and outcomes including recurrent ICH, ischaemic stroke, and acute coronary syndrome were checked from hospital records. Of these 440 patients, 56 patients (12.7%) were prescribed aspirin (312 patientaspirin years). After a follow-up of 62.2 &#177; 1.8 months, 47 patients had recurrent ICH (10.7%, 20.6 per 1,000 patient years). Patients prescribed aspirin did not have a higher risk of recurrent ICH compared with those not prescribed aspirin (22.7 per 1,000 patient-aspirin years vs. 22.4 per 1,000 patient years, p=0.70). Multivariate analysis identified age &gt; 60 years (hazard ratio [HR]: 2.0, 95% confidence interval [CI]: 1.07-3.85, p=0.03) and hypertension (HR: 2.0, 95% CI: 1.06-3.75, p=0.03) as independent predictors for recurrent ICH. In a subgroup analysis including 127 patients with standard indications for aspirin of whom 56 were prescribed aspirin, the incidence of combined vascular events including recurrent ICH, ischaemic stroke, and acute coronary syndrome was statistically lower in patients prescribed aspirin than those not prescribed aspirin (52.4 per 1,000 patient-aspirin years, vs. 112.8 per 1,000 patient- years, p=0.04). In conclusion, we observed in a cohort of Chinese post-ICH patients that aspirin use was not associated with an increased risk for a recurrent ICH. &#169; Schattauer 2012.</description.abstract>
<language>eng</language>
<publisher>Schattauer GmbH. The Journal&apos;s web site is located at http://www.thrombosis-online.com</publisher>
<relation.ispartof>Thrombosis and Haemostasis</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject>Antiplatelet agents</subject>
<subject>Risk factors</subject>
<subject>Stroke/prevention</subject>
<subject.mesh>Age Factors</subject.mesh>
<subject.mesh>Aspirin - administration &amp; dosage - adverse effects</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Follow-Up Studies</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Intracranial Hemorrhages - drug therapy - physiopathology - surgery</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Platelet Aggregation Inhibitors - administration &amp; dosage - adverse effects</subject.mesh>
<subject.mesh>Recurrence</subject.mesh>
<subject.mesh>Registries</subject.mesh>
<subject.mesh>Risk Factors</subject.mesh>
<subject.mesh>Treatment Outcome</subject.mesh>
<title>Use of aspirin in Chinese after recovery from primary intracranial haemorrhage</title>
<type>Article</type>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1160/TH11-06-0439</identifier.doi>
<identifier.pmid>22187066</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84856638385</identifier.scopus>
<identifier.hkuros>198412</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84856638385&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>107</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>241</identifier.spage>
<identifier.epage>247</identifier.epage>
<identifier.isi>WOS:000300748800005</identifier.isi>
<publisher.place>Germany</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/144558/1/content.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong Li Ka Shing Faculty of Medicine